Weight-Loss drug trial aims to protect arthritis Patients' hearts
NCT ID NCT07251556
Summary
This study is testing if a GLP-1 receptor agonist drug (semaglutide) can help control hidden heart disease risk in people with psoriatic arthritis who do not have diabetes. It will enroll 40 participants to see if the drug can slow the progression of artery thickening and stiffness over 24 weeks. The goal is to see if this medication, known for heart benefits in diabetes, can also protect the cardiovascular health of people with this inflammatory arthritis.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.